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Breast cancer and pregnancy
G. K. Azada, A. E. Ringb
aGuy’s Hospital, St Thomas Street, London, UK; bRoyal Sussex County Hospital, Eastern Road,
Brighton, UK.
Abstract Breast cancer is one of the most commonly diagnosed cancers in pregnant women. Diagnosis and
treatment in these women are particularly challenging as the necessary investigations and treatment modali-
ties may potentially harm the developing foetus. Nonetheless, it appears that initial diagnostic investigations
may be carried out as for non-pregnant women, but bearing in mind the risks of exposing the foetus to ionising
radiation. Surgery can be carried out with little risk to the mother or foetus but radiotherapy is generally
avoided. Chemotherapy can be given relatively safely when administered after the first trimester, but large
volume prospective data and, in particular, data regarding the long-term implications of in utero exposure, are
awaited.
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Epidemiology of breast cancer in pregnancy
It is estimated that 1 in 3000 pregnancies are com-
plicated by breast cancer, and the incidence is
expected to rise as more women in developed
countries delay childbearing until later in life [1–5].
There is no consensus in the literature as to what
comprises ‘pregnancy-associated breast cancer’,
with some authors including only breast cancers
diagnosed in women who are pregnant at the time
of diagnosis, and others also including breast
cancers diagnosed within a year postpartum or during
lactation.
Principles of treating breast cancer in
pregnant women
An appreciation of the stages of in utero develop-
ment is critical to the appropriate management of
these patients. Implantation usually occurs within
two weeks following conception. In humans the
internal organs develop their structure within the
third to eighth weeks in utero (the period of orga-
nogenesis). Insults, pharmacological or physical, to
the foetus during this period may manifest as major
malformations, or as foetal loss. However, after the
first trimester organogenesis is complete and the
risks of major malformations are minimal, although
it should be recognised that the gonads and the
central nervous system continue to develop later in
foetal life. The rest of uterine life largely consists of
growth and maturation of the foetus, processes that
appear to be less-obviously susceptible to the
effects of pharmacological and physical damage.
Diagnosing breast cancer in
pregnant women
As for non-pregnant women, the diagnostic path-
way should comprise clinical examination, imaging
and pathological assessments. However, during
pregnancy, clinical breast examination can be diffi-
cult as the breasts become firmer and more nodular
as a result of glandular proliferation. Mammograms
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are often not performed, not just because of con-
cerns regarding harm to the foetus from ionising
radiation, but also because the increased breast
density in pregnancy makes them more difficult
to interpret. (However, it should be recognised
that mammography may identify extensive micro-
calcifications, a finding that may alter management
if a wide-local excision is being considered.) Ultra-
sound is more frequently used as the imaging
modality of choice, particularly as most women
present with a lump. There is very limited data
concerning the utility of magnetic resonance ima-
ging (MRI) to diagnose primary breast cancers, and
there are difficulties with positioning the patient
prone and concerns regarding the safety of gado-
linium contrast agent [6].
Staging investigations should be carried out
where appropriate, taking into consideration the
risks to the foetus and the extent to which a positive
result will immediately effect management. The
issue of exposure to ionising radiation in pregnancy
is one which creates a great deal of concern among
physicians and patients, but in fact when one con-
siders chest X-rays and mammograms the risks are
probably minimal [7,8]. However, CT scans may
expose the foetus to higher doses of radiation and
are usually avoided. Metastases may be sought
using other imaging modalities such as ultra-
sonography or MRI [9].
Histopathological features of breast cancer
in pregnancy
In pregnant women, the histopathological and
immunohistochemical findings of breast cancer are
found to be similar to those of non-pregnant young
women, indicating that the biological features of
the cancer are most likely determined by the age of
the patient at diagnosis [10]. A large proportion of the
tumours diagnosed during pregnancy are high grade,
display lymphovascular invasion and involve the
axillary lymph nodes [10–12]. Approximately 60–80%
of breast cancers during pregnancy are reported to
be oestrogen receptor (ER) negative and between
28% and 58% are said to be HER2 positive [13].
These features are similar to those we would expect
in pre menopausal non-pregnant women.
Treatment of pregnancy-associated
breast cancer
The treatment of a woman diagnosed with breast
cancer while pregnant presents a challenge to all of
those involved in their care. The data we currently
use to make management decisions in pregnancy-
associated breast cancer are incomplete and
continue to evolve. However it is possible to draw
some conclusions from the information that we do
have. The treatment offered depends on the stage of
the cancer, the gestational age at first presentation
and patient preferences.
Surgery
Surgery is the first line of treatment for most women
with breast cancer, including those who are preg-
nant. Breast surgery, including general anaesthesia,
can be performed with minimal risk to the foetus at
all stages of pregnancy [14,15]. Historically, most
pregnant women were offered a mastectomy owing
to high local recurrence rates and in the hope of
avoiding adjuvant radiotherapy, which is relatively
contraindicated in pregnancy [12,16]. However,
increasingly young women are offered postoperative
adjuvant chemotherapy while pregnant with radio-
therapy delayed until after delivery, meaning that
breast-conserving surgery has become a reasonable
option. An alternative approach is to offer neo-
adjuvant medical therapy in pregnancy and delay
surgery until postpartum [17,18]. Depending on
gestational age and patient preferences, this may be
a very reasonable option. The safety of sentinel
lymph node biopsy in pregnancy is unknown. Some
studies suggest that the amount of radiation deli-
vered through the use of technetium for a sentinel
node biopsy is as low as 4.3mGy and could be
offered to patients [19,20].
Systemic treatment
Data on the use of chemotherapy during pregnancy
are limited to case reports and small case series. It
appears that most anti-neoplastic drugs have the
potential to cross the placenta, and by virtue of
their mechanism of action could potentially harm
the foetus. A second major consideration is that
physiological changes associated with pregnancy
affect drug pharmacokinetics and complicate cor-
rect dosing of chemotherapy agents, such that not
only may the foetus be put at even greater risk but
also the mother may not be treated optimally.
One might predict from knowledge of in utero
development that the foetus would be at greatest
risk of harm in the first trimester, and in particular
during organogenesis. Indeed, when chemothe-
rapy is given during the first trimester, the risk of
malformations is approximately 10–20% [21–23].
However, when chemotherapy is administered in
the third trimester, the rate of congenital mal-
formations has been reported as approximately
3%, which is similar to the baseline population risk
of major malformations [24]. Hence, chemotherapy
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is usually avoided during the early embryonic period
due to potential damage to the foetus. Chemo-
therapy-related problems are not just restricted to
intra-uterine life, there can be a potential risk of
sepsis and haemorrhage if the mother develops
bone marrow suppression secondary to treatment
and then delivers the baby. Neonatal cytopenias
have been reported concomitantly with maternal
low blood counts, which can pose a significant risk
for the newborn [25]. Hence, delivering chemo-
therapy even in the second and third trimesters can
sometimes prove potentially dangerous.
The regimens for which the most information is
available are the anthracycline-based regimens.
The MD Anderson series is a prospective body of
evidence which shows that fluorouracil, Adriamycin
and cyclophosphamide (FAC) chemotherapy can be
given in the second/third trimester of pregnancy
with minimal risk to the foetus, assuming that che-
motherapy is not administered around the time of
delivery [26]. There is minimal data available con-
cerning the use of taxanes in pregnancy-associated
breast cancer, but a handful of case reports indicate
no greater risk with use of taxane-based prepara-
tions [13,27]. The potential implications of in utero
chemotherapy exposure for long-term neurological,
educational and cardiac development in the off-
spring, and also in the fertility of the offspring, are
unknown. It is incumbent upon us to continue to
improve the limited knowledge we have regarding
this issue. The way to tackle this situation is through
observation and reassessment of outcomes of
pregnant women who received chemotherapy for
breast cancer through national and international
registry studies.
Trastuzumab has been used in the treatment of
pregnancy-associated breast cancer without any
adverse effects [28], and with reversible anhy-
dramnios and renal failure [29]. However, the long-
term implications of exposure to this and other
targeted treatments in pregnancy are unclear [30].
Hormonal treatment, if indicated, is usually deferred
until after delivery. Some case reports highlight
the safe delivery of tamoxifen in metastatic breast
cancer [31,32], whereas others report birth defects
like Goldenhar syndrome [33] and ambiguous
genitalia [34].
Medications like anti-emetics and steroids can
usually be administered during the course of che-
motherapy without any adverse effects [35]. 5HT3
antagonists like ondansetron have not been repor-
ted to cause any malformations [36,37]. One case–
control study has highlighted the association
between the use of corticosteroids in the first
trimester and the occurrence of cleft palate in the
newborn; hence, steroids should probably be
avoided in the first trimester [38]. Granulocyte col-
ony-stimulating factors (GCSF) and erythropoietin
have been safely used in pregnancy and the current
recommendations for the use of white blood cell
growth factors should be followed [39,40].
Radiotherapy
As with any ionising radiation exposure, there is the
risk with radiotherapy of inducing foetal loss, mal-
formations or growth retardation. In the treatment of
breast cancer, a standard dose of 50–60Gy is used
to radiate the breast tissue/chest wall and the foe-
tus could receive up to 2 cGy in the first trimester,
24.6 cGy in the second trimester and up to 58.6 cGy
in the third trimester [7]. Radiation doses of 10–
90 cGy have been associated with detrimental con-
sequences [41]. Therefore in pregnancy-associated
breast cancer radiotherapy is usually deferred till
after delivery. However, there have been some
reported cases of radiotherapy use in pregnant
breast cancer patients [42]. Under these circum-
stances, the potential of radiotherapy to harm the
foetus has to be weighed up against improvements
in recurrence-free survival and overall mortality from
breast cancer.
Genetic counselling
Up to 10% of breast cancers have an inherited
basis. These cancers may occur as a result of
inheriting an altered BRCA1 or BRCA2 gene.
Women with a mutation in either gene are at an
increased risk for early-onset breast cancer,
bilateral breast cancer and ovarian cancer. Women
with pregnancy-associated breast cancer have an
increased risk for these predisposing mutations,
hence genetic counselling is recommended for all
these women. In one Swedish study, more women
with pregnancy-associated breast cancers had a
BRCA1 mutation rather than a BRCA2 mutation
[43]. Genetic counselling combined with genetic
testing may help women to make important deci-
sions about medical care and cancer screening.
Psychological counselling
The diagnosis of breast cancer during pregnancy will
certainly cause shock, anxiety and depression to any
woman and the members of her family. Patients
should be offered the opportunity to discuss some of
the complex decisions in a supportive environment
with a skilled counsellor, especially if they have diffi-
culty coping with making major life decisions sooner
than expected. Also, getting such women in contact
with other younger women who have pregnancy-
associated breast cancer may help.
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Prognosis of breast cancer in pregnancy
Historically, pregnancy-associated breast cancer
has been assumed to have a particularly poor
prognosis, with 5-year survivals in the region of
20–30%. However, initial case series were not
necessarily compared with appropriate matched
control cases, taking into account important patient
and pathological variables, such as young age,
grade of tumour and ER status. Where this has
been done, and if one makes allowances for the fact
that many of these women did not receive optimal
treatment, there is probably little difference in
survival between pregnancy-associated and non-
pregnancy-associated breast cancer [44–46].
Discussion
The treatment of women with breast cancer diag-
nosed in pregnancy poses a unique challenge to
the health care professionals involved in their care.
Treatment should be instigated by the multi-
disciplinary team such that a consensus to man-
agement is made. Initial investigations can be
carried out as for non-pregnant women bearing in
mind the adverse effects of ionising radiation to the
foetus. Surgery can be carried out without much
risk, but radiotherapy is generally avoided. Chemo-
therapy can be administered safely after the first
trimester but is avoided around the time of delivery
in order to prevent complications related to cyto-
penias. Under these circumstances there is little
evidence to suggest that chemotherapy has sig-
nificant short-term implications for the foetus or the
mother, but the long-term implications of such
exposure remain unknown.
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